Discovery of a Transferrin Receptor 1‑Binding Aptamer and Its Application in Cancer Cell Depletion for Adoptive T‑Cell Therapy Manufacturing

• Published in: Journal of the American Chemical Society 2022-08, Vol.144 (30), p.13851-13864
• Main Authors: Cheng, Emmeline L., Cardle, Ian I., Kacherovsky, Nataly, Bansia, Harsh, Wang, Tong, Zhou, Yunshi, Raman, Jai, Yen, Albert, Gutierrez, Dominique, Salipante, Stephen J., des Georges, Amédée, Jensen, Michael C., Pun, Suzie H.
• Format: Article
• Language: English
• Subjects: Cell- and Tissue-Based Therapy; Humans; Leukocytes, Mononuclear; Neoplasms - metabolism; Receptors, Antigen, T-Cell - metabolism; Receptors, Chimeric Antigen - genetics; Receptors, Transferrin - metabolism; T-Lymphocytes
• ISSN: 0002-7863; 1520-5126
• DOI: 10.1021/jacs.2c05349

The clinical manufacturing of chimeric antigen receptor (CAR) T cells includes cell selection, activation, gene transduction, and expansion. While the method of T-cell selection varies across companies, current methods do not actively eliminate the cancer cells in the patient’s apheresis product from the healthy immune cells. Alarmingly, it has been found that transduction of a single leukemic B cell with the CAR gene can confer resistance to CAR T-cell therapy and lead to treatment failure. In this study, we report the identification of a novel high-affinity DNA aptamer, termed tJBA8.1, that binds transferrin receptor 1 (TfR1), a receptor broadly upregulated by cancer cells. Using competition assays, high resolution cryo-EM, and de novo model building of the aptamer into the resulting electron density, we reveal that tJBA8.1 shares a binding site on TfR1 with holo-transferrin, the natural ligand of TfR1. We use tJBA8.1 to effectively deplete B lymphoma cells spiked into peripheral blood mononuclear cells with minimal impact on the healthy immune cell composition. Lastly, we present opportunities for affinity improvement of tJBA8.1. As TfR1 expression is broadly upregulated in many cancers, including difficult-to-treat T-cell leukemias and lymphomas, our work provides a facile, universal, and inexpensive approach for comprehensively removing cancerous cells from patient apheresis products for safe manufacturing of adoptive T-cell therapies.